Patent US514806A successfully refreshed from Google Patents.
US3879554A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of 1,6-dimethyl-8-{62 -(5-bromonicotinoyloxymethyl)-10 {60 -methoxyergoline in treating cerebral and peripheral metabolic vascular disorders
Assignee: Pfizer Italia SRL
•
Filing: 1973-04-02
•
Granted: 1975-04-22
•
Expires: 1993-04-02
Abstract
Abstract 1,6-DIMETHYL-8 BETA-(5-BROMONICOTINOYL-OXYMETHYL)-10 ALPHAMETHOXY-ERGOLINE, WHICH HAS BEEN GIVEN THE NAME ''''Nicergoline'''' and constitutes a new drug active on cerebral and peripheral metabolic-vascular disorders.
Inventors
- 👤 Aldemio Temperilli
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 04:39
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/475
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
53 words
A METHOD OF INHABITING BLOOD PLATELET AGGREGATION IN THE TREATMENT OF A CEREBRAL AND PERIPHERAL METABOLIC VASCULAR DISORDER SELECTED FROM THE GROUP CONSISTING OF CEREBRAL AND PERIPHERAL ARTERIOSCLEROSIS, RAYNAUD''S DISEASE, VASCULAR CEPHALAGIA AND MIGRANIE, WHICH COMPRISES ADMINISTERING TO A HUMAN HOST AN AMOUNT OF THE COMPOUND 1,6-DIMETHYL-8-B-(5BROMO-NICOTINOYLOXYMETHYL)-10-A-METHOXYERGOLINE EFFECTIVE TO INHABIT BLOOD PLATELET AGGREGATION.
Claim 2
Independent Claim
53 words
A METHOD OF INHABITING BLOOD PLATELET AGGREGATION IN THE TREATMENT OF A CEREBRAL AND PERIPHERAL METABOLIC VASCULAR DISORDER SELECTED FROM THE GROUP CONSISTING OF CEREBRAL AND PERIPHERAL ARTERIOSCLEROSIS, RAYNAUD''S DISEASE, VASCULAR CEPHALAGIA AND MIGRANIE, WHICH COMPRISES ADMINISTERING TO A HUMAN HOST AN AMOUNT OF THE COMPOUND 1,6-DIMETHYL-8-B-(5BROMO-NICOTINOYLOXYMETHYL)-10-A-METHOXYERGOLINE EFFECTIVE TO INHABIT BLOOD PLATELET AGGREGATION.
Claim 3
Independent Claim
57 words
A method of inhibiting blood platelet aggregation in the treatment of a cerebral and peripheral metabolic vascular disorder selected from the group consisting of cerebral and peripheral arteriosclerosis, Raynaud''s disease, vascular cephalagia and migraine, which comprises administering to a human host an amount of the compound 1,6-dimethyl-8- Beta -(5-bromo-nicotinoyloxymethyl)-10- Alpha -methoxyergoline effective to inhibit blood platelet aggregation.
Claim 4
Independent Claim
57 words
A method of inhibiting blood platelet aggregation in the treatment of a cerebral and peripheral metabolic vascular disorder selected from the group consisting of cerebral and peripheral arteriosclerosis, Raynaud''s disease, vascular cephalagia and migraine, which comprises administering to a human host an amount of the compound 1,6-dimethyl-8- Beta -(5-bromo-nicotinoyloxymethyl)-10- Alpha -methoxyergoline effective to inhibit blood platelet aggregation.
References Cited (Backward Citations)
US3228943A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-04-21 | 1978-10-21 | 1979-04-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-04-21 | 1982-10-21 | 1983-04-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-04-21 | 1986-10-21 | 1987-04-22 | $7700.00 | Window Closed / Lapsed |